{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:19:40Z","timestamp":1778570380447,"version":"3.51.4"},"reference-count":33,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>PERSIST was a prospective, non\u2010interventional, long\u2010term, German multicentre study of patients with moderate\u2010to\u2010severe psoriasis receiving guselkumab, an approved monoclonal antibody that binds to the p19 subunit of interleukin (IL)\u201023, in a real\u2010world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Evaluation of the efficacy and safety of guselkumab, and its effect on health\u2010related quality of life (HRQoL), in patients with moderate\u2010to\u2010severe psoriasis who have received 52\u2009weeks of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients (\u226518\u2009years old) were prescribed guselkumab as per routine clinical practice. End points assessed include Psoriasis Area and Severity Index (PASI), Physician's Global Assessment (PGA), target Nail Psoriasis Severity Index (NAPSI), and the Dermatology Life Quality Index (DLQI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 303 patients were enrolled and treated with guselkumab. Mean disease duration was 21.0\u2009years, and 77.2% and 51.2% of patients had received \u22651 prior conventional systemic or \u22651 prior biologic therapy, respectively. Mean PASI score decreased from 16.4 at baseline to 3.0 by Week (W) 28, and further decreased to 2.4 by W52, while the proportion of patients achieving an absolute PASI score of \u22641 increased from 1.3% at baseline, to 50.8% at W28 and to 58.4% by W52. PASI90 and PASI100 responses also showed marked improvements between W28 and W52, regardless of biologic treatment history. Clearance of psoriatic skin was observed in difficult\u2010to\u2010treat areas, with the percentage of patients achieving a PGA score\u2009\u22641 increasing between W28 and W52. Guselkumab improved HRQoL; mean DLQI score decreased from 13.7 at baseline to 2.8 by W28, and further decreased to 2.4 by W52. At W52, 64.6% of patients achieved a DLQI score\u2009\u22641. The cumulative probability of drug survival was 92.4% at W52.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Guselkumab is efficacious and well tolerated regardless of previous biologic therapies, comorbidities or psoriasis manifestation in difficult\u2010to\u2010treat areas. No new safety signals were observed.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.18218","type":"journal-article","created":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T07:54:09Z","timestamp":1652601249000},"page":"1568-1577","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Real\u2010world evidence from the non\u2010interventional, prospective, German multicentre <scp>PERSIST<\/scp> study of patients with psoriasis after 1\u2009year of treatment with guselkumab"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6667-7757","authenticated-orcid":false,"given":"S.","family":"Gerdes","sequence":"first","affiliation":[{"name":"Psoriasis Center Kiel, Department of Dermatology University Medical Center Schleswig\u2010Holstein, Campus Kiel  Kiel Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Asadullah","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin  Berlin Germany"},{"name":"Prof. Dr. med. Asadullah, Hautarztpraxis  Potsdam Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Dermatology Practice Dr. Matthias Hoffmann  Witten Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Korge","sequence":"additional","affiliation":[{"name":"Dermatology Practice Dr. Bernhard Korge  D\u00fcren Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Mortazawi","sequence":"additional","affiliation":[{"name":"Dermatology Practice Dr. Dariusch Mortazawi  Remscheid Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Wegner","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH, MAF  Neuss Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8631-518X","authenticated-orcid":false,"given":"Y.","family":"Personke","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH, MAF  Neuss Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gomez","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH, MAF  Neuss Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sticherling","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital of Erlangen, Deutsches Zentrum f\u00fcr Immuntherapie  Erlangen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1252022"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07405.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1348\/014466502163949"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200506060-00005"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.065"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16568"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072170"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-016-1637-8"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2013.814957"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-016-1651-x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0800-7"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.040"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17454"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00555-7"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16511"},{"key":"e_1_2_7_20_1","first-page":"406","article-title":"Real\u2010world effectiveness and safety of guselkumab for the treatment of psoriasis: a 6\u2010month prospective study in a series of psoriatic patients","volume":"25","author":"Malara G","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475420932514"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1800577"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13344"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14798"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13964"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.16128"},{"key":"e_1_2_7_27_1","first-page":"48","article-title":"German psoriasis registry PsoBest: objectives, methodology and baseline data","volume":"12","author":"Augustin M","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13908"},{"key":"e_1_2_7_29_1","unstructured":"ArmstrongA DuffinK FitzgeraldTet\u2009al. Impact of guselkumab on quality of life and work productivity outcomes among patients with moderate\u2010to\u2010severe plaque psoriasis in the Corrona Psoriasis Registry. In:2021 American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX); 23\u201325 April 2021; poster."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-020-00099-7"},{"key":"e_1_2_7_31_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235091","article-title":"Sex\u2010related impairment and patient needs\/benefits in anogenital psoriasis: difficult\u2010to\u2010communicate topics and their impact on patient\u2010centred care","volume":"15","author":"Silva N","year":"2020","journal-title":"PLoS One"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10249.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010021\u201000598\u20104"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1488963"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18218","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18218","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T07:33:55Z","timestamp":1721633635000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/jdv.18218"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18218","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]},"assertion":[{"value":"2021-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}